UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Early identification of golimumab-treated patients with higher likelihood of long-term retention

Frontiers in immunology, 2024, Vol.15, p.1359571-1359571

2024

Link zum Volltext

Verfügbarkeit prüfen

Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

Advances in rheumatology (London, England), 2023-06, Vol.63 (1), p.25-25, Article 25

2023

Link zum Volltext

Verfügbarkeit prüfen

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

Pain (Amsterdam), 2020-09, Vol.161 (9), p.2068

2020

Link zum Volltext

Verfügbarkeit prüfen

Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial

Pain practice, 2016-06, Vol.16 (5), p.600-619

2016

Link zum Volltext

Verfügbarkeit prüfen

Reference genes for normalization of gene expression studies in human osteoarthritic articular cartilage

BMC molecular biology, 2008-01, Vol.9 (1), p.17-17, Article 17

2008

Link zum Volltext

Verfügbarkeit prüfen

Retention of golimumab treatment following discontinuation of non‐TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry

Musculoskeletal care, 2022-06, Vol.20 (2), p.403-407

2022

Link zum Volltext

Verfügbarkeit prüfen

Infection by Mycobacterium chelonae at the site of administration of sarilumab for rheumatoid arthritis

Rheumatology (Oxford, England), 2020-01, Vol.59 (1), p.265-265

2020

Link zum Volltext

Verfügbarkeit prüfen

Genetic risk load and age at symptom onset of knee osteoarthritis

Journal of orthopaedic research, 2012-06, Vol.30 (6), p.905-909

2012

Link zum Volltext

Verfügbarkeit prüfen

Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain

Patient preference and adherence, 2021-01, Vol.15, p.111-117

2021

Link zum Volltext

Verfügbarkeit prüfen

The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs

Pharmacological research, 2019-10, Vol.148, p.104410-104410, Article 104410

2019

Link zum Volltext

Verfügbarkeit prüfen

European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response

Rheumatology (Oxford, England), 2021-12

2021

Link zum Volltext

Verfügbarkeit prüfen

Abatacept for the treatment of rheumatoid arthritis

Expert review of clinical immunology, 2019-04, Vol.15 (4), p.319-326

2019

Link zum Volltext

Verfügbarkeit prüfen

After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries

Annals of the rheumatic diseases, 2023-02, Vol.82 (2), p.175

2023

Link zum Volltext

Verfügbarkeit prüfen

Functional analysis of the osteoarthritis susceptibility–associated GDF5 regulatory polymorphism

Arthritis and rheumatism, 2009-07, Vol.60 (7), p.2055-2064

2009

Link zum Volltext

Verfügbarkeit prüfen

Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

Arthritis care & research (2010), 2022-07, Vol.74 (7), p.1205-1218

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis

Seminars in arthritis and rheumatism, 2020-02, Vol.50 (1), p.17-24

2020

Link zum Volltext

Verfügbarkeit prüfen

Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution

Rheumatology (Oxford, England), 2019-12, Vol.58 (12), p.2221-2229

2019

Link zum Volltext

Verfügbarkeit prüfen

An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage

Human molecular genetics, 2007-09, Vol.16 (18), p.2226-2232

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(35)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Humans
(25)
Rheumatology
(24)
Rheumatoid Arthritis
(16)
Female
(14)
Antirheumatic Agents - Therapeutic Use
(13)
Arthritis, Rheumatoid - Drug Therapy
(13)
Male
(13)
Treatment Outcome
(12)
Middle Aged
(11)
Medicin Och Hälsovetenskap
(10)
Psoriatic Arthritis
(10)
Aged
(8)
Axial Spondyloarthritis
(8)
Epidemiology
(8)
Patients
(8)
Registries
(8)
Tnf Inhibitors
(8)
Retention
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Early identification of golimumab-treated patients with higher likelihood of long-term retention

Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial

The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries

Reference genes for normalization of gene expression studies in human osteoarthritic articular cartilage

Retention of golimumab treatment following discontinuation of non‐TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry

Infection by Mycobacterium chelonae at the site of administration of sarilumab for rheumatoid arthritis

Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

Genetic risk load and age at symptom onset of knee osteoarthritis

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis

Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain

The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs

European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

Abatacept for the treatment of rheumatoid arthritis

After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries

Functional analysis of the osteoarthritis susceptibility–associated GDF5 regulatory polymorphism

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)

Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis

Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution

An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage

Suchergebnisse filtern